Navigation Links
Cardiome And Astellas Announce Regulatory Update
Date:1/21/2008

F="http://www.astellas.com/us" target="_new">http://www.astellas.com/us.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing.

Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we m
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Hold Investor Update Call
2. Cardiome Updates Guidance
3. Cardiome Initiates Phase 1 Study for GED-aPC
4. Cardiome To Release Third Quarter Results
5. Cardiome to Present at CIBC Conference
6. Cardiome to Present at ThinkEquity Conference
7. Cardiome to Present at Bear Stearns Conference
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
10. Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... TX (PRWEB) , ... August 31, 2015 , ... ... EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on a ... The eye-catching campaign image is designed to inspire and promote earlier awareness of ...
(Date:8/31/2015)... Ann Arbor, Michigan (PRWEB) , ... August 31, ... ... writes standards, and tests and certifies products for the water, food, health sciences ... as complying with NSF/ANSI 61 for their advanced iron filtration media, Pro-OX Manganese ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 30, 2015 , ... ProTrailer Party is a new and exciting set of ... styled and detailed presets, allowing FCPX users to immerse the audience into the party. ... film makers save time while adding professional titles to every project. , ProTrailer Party ...
(Date:8/30/2015)... ... ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging FDA Findings, **FDAnews ... , US authorities are holding imports more than ever before, particularly at ports that ... an uptick and a new final rule, having a top-notch import compliance program is ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3
... for,Protective Coatings is pleased to announce that the ... of certification credits,for industrial hygienists who pass the ... Refresher (C-5) training courses. ABIH is a non-profit,professional ... of industrial hygiene and is the certifying organization ...
... House Science and Technology Committee for Holding Health IT ... ... IT Now!,Coalition, co-chaired by former Sen. John Breaux and former Rep. Nancy,Johnson, ... session. "It,s time for Congress to act so that our health ...
... ) announced today the final tabulation of votes at its,Annual Meeting ... -- Shareholders voted to adopt the merger agreement with ... to approve the merger agreement. Approval ... vote of a majority of shares voting on this ...
... SEIU United Healthcare,Workers-West and SEIU Local ... stop Tenet Healthcare Corp. from cutting health ... registered nurses,pharmacists, licensed vocational nurses, respiratory care ... Workers represented by the two unions ...
... Ramps ... Million, CHICAGO, Sept. 26 Since its launch in April, more ... and have lost more than three-quarters of a million pounds.,Challenge founder Dr. ... will lead the way to a million pounds lost by the,final stop ...
... tension, ... avoid tissue damage, ANDOVER, Mass., Sept. 26 Smith ... launch of the,KINSA RC 5.5 Suture Anchor, designed to provide secure repair ... of muscles,and tendons that control shoulder motion. Surgeons can repair these ...
Cached Medicine News:Health News:ABIH Approves Certification Credit for SSPC Training Courses 2Health News:Health IT Now! Coalition Calls on Congress to Pass Health Information Technology Legislation This Year 2Health News:Arrow International Announces Annual Meeting Voting Results 2Health News:Unions File Charges Against Tenet Healthcare Corporation 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 2Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 4
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... presented at 12th Congress of European Hematology ... -- Alexion,Pharmaceuticals, Inc. today announced results from ... (eculizumab) for the,treatment of paroxysmal nocturnal hemoglobinuria ... organized by The European,Hematology Association (EHA) in ...
... over Placebo Larger at One Year than at ... 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the,benefits ... 2 study in mild-to- moderate Alzheimer's,disease were statistically ... Importantly, on every endpoint studied, the benefits,of Dimebon ...
Cached Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: